Anaphylaxis: A Rare Disease

Anaphylaxis is a rare disease which can even result in life-threatening situations. Mostly the allergic reaction is due to food, insect stings, medications and latex. 

Usually, the symptoms are expressed in one part of the body; however, in some instances, the reaction is severe. Sometimes, a specific type of aerobic exercise can be a trigger cause of the disease. 

Some of the common triggers of anaphylaxis cover a variety of foods, drugs and insect venoms. 

The symptoms of anaphylaxis commence within 5 to 30 minutes or in a few cases, it may take more than an hour for getting noticed anaphylactic symptoms while coming into contact with the allergen.

The signs typically affect more than one part of the body and may include: red rash, swollen throat, wheezing, passing out, chest tightness, trouble breathing, cough, hoarse voice, trouble swallowing, vomiting, diarrhoea, stomach cramping, pale or red colour to the face and body.

The affected people may require immediate medical treatment, including a prompt injection of epinephrine.

Adrenaline (epinephrine) is the initial treatment of choice for anaphylaxis. The patient’s airway, breathing and circulation need to be assessed, monitored, and managed. In addition to adrenaline, oxygen and inhaled beta‐2 agonists are used in the case of breathing difficulties and volume expanders are used in the case of hypotension. As adjuvant therapies, H1‐ and H2‐antihistamines and steroids are also often given, although there is little data to support these uses and in the case of first‐generation, potentially sedating H1‐antihistamine preparations, there is potential to cause harm.

Anaphylaxis treatment market has been segmented into the regions like Europe, North America, Latin America, Asia-Pacific, and Middle East & Africa.

It is anticipated that North America will lead the anaphylaxis treatment market due to a rise in the anaphylaxis incidence, changes in lifestyle, and increasing awareness regarding anaphylaxis treatment among healthcare professionals. 

The anaphylaxis treatment market in Europe is expected to grow at an increased rate because of increased acquisition of the novel technologies in the anaphylaxis treatment.

The anaphylaxis treatment market of Asia Pacific anticipated rising at a fast rate due to substantial pool patients, accompanying with rising medical unmet need in the region.

There is a slew of market players like ALK-Abelló, Impax Laboratories Inc., Lincoln Medical Ltd., Mylan NV, Adamis Pharmaceutical Corporation, MannKind Corporation, Pfizer Inc., GlaxoSmithKline Plc., Merck & Co., Inc. in Anaphylaxis treatment market.